Simu Gluclipide will soon face a wave of domestic generic imitations.

The patent protection period for Novo Nordisk's semaglutide core compound in China officially ends on March 20, 2026. This means that in the future, once generic semaglutide drugs are approved, a major obstacle to their market sales will be cleared, and prices are expected to be lower. According to Novo Nordisk's annual report, in 2025, global sales of semaglutide product series are expected to be around 228.288 billion Danish kroner, contributing over seventy percent to the company's total revenue. In the Chinese market, sales of semaglutide are expected to be around 6.815 billion Danish kroner. Novo Nordisk predicts that, based on fixed exchange rates excluding exchange rate impacts, the company's sales in 2026 will decline by 5% to 13% compared to the previous year. This is due to factors such as the U.S. Most Favored Nation treatment agreement, the expiration of patents for semaglutide molecules in some markets, and market competition. The domestic market for generic semaglutide drugs in China has already attracted many players. Interface News found in the Morin Medicine Database that there are already about 10 domestic generic semaglutide drugs in the market application stage, and many more drugs are in clinical trials.